ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Rigel Pharmaceuticals, Inc." (RIGL) Report Updated: Sep 26, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Rigel Pharmaceuticals, Inc." (RIGL)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Biotechnology
Competitors: MDVN,SPHS,PIP,EXEL

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: B down upgrade
Last Week: C same downgrade
Two Weeks Ago: B up upgrade
service keys

"Rigel Pharmaceuticals, Inc."© quotemedia

Company Profile

Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. It is developing fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura and Phase II clinical trials for IgA nephropathy; R348, a topical JAK/SYK inhibitor that is in Phase II clinical trials for the treatment of dry eye in ocular graft-versus-host disease; and two oncology product candidates in Phase I development. The company has a license agreement with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; a license agreement with BerGenBio AS for the development and commercialization of an oncology program; a collaboration agreement with Daiichi Sankyo to pursue research related to a specific target from a class of drug targets called ligases that control cancer cell proliferation through protein degradation; and a collaboration agreement with Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies. Rigel Pharmaceuticals, Inc. was founded in 1996 and is based in South San Francisco, California.